Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 227-231 |
| Number of pages | 5 |
| Journal | Journal of Evidence-Based Medicine |
| Volume | 12 |
| Issue number | 3 |
| Early online date | 22 Aug 2019 |
| DOIs | |
| Publication status | Published - Aug 2019 |
Fingerprint
Keywords
- Anticholinergics
- deprescribing
- intervention development
- qualitative research
- systematic review
ASJC Scopus subject areas
- Health Policy
Cite this
Barriers and facilitators to reducing anticholinergic burden from the perspectives of patients, their carers, and healthcare professionals : A protocol for qualitative evidence synthesis. / Stewart, Carrie (Corresponding Author); Gallacher, Katie; Nakham, Athagran; Cruickshank, Moira; Newlands, Rumana; Bond, Christine; Myint, Phyo K.; Bhattacharya, Debi; Mair, Frances S.
In: Journal of Evidence-Based Medicine, Vol. 12, No. 3, 08.2019, p. 227-231.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Barriers and facilitators to reducing anticholinergic burden from the perspectives of patients, their carers, and healthcare professionals
T2 - A protocol for qualitative evidence synthesis
AU - Stewart, Carrie
AU - Gallacher, Katie
AU - Nakham, Athagran
AU - Cruickshank, Moira
AU - Newlands, Rumana
AU - Bond, Christine
AU - Myint, Phyo K.
AU - Bhattacharya, Debi
AU - Mair, Frances S.
N1 - ACKNOWLEDGMENTS This review is funded by The Dunhill Medical Trust (RPGF1806/66) as part of a series of work building an evidence synthesis suite to inform a future randomized trial of reducing anticholinergic related harm in older adults. The funding sponsors had no role in the design, execution, interpretation, or writing of the study.
PY - 2019/8
Y1 - 2019/8
N2 - Anticholinergic drugs are prescribed for a range of conditions including gastrointestinal disorders, overactive bladder, allergies, and depression. While in some circumstances anticholinergic effects are therapeutic, they also pose many undesired or adverse effects. The overall impact from concomitant use of multiple medications with anticholinergic properties is termed anticholinergic burden (ACB). Greater ACB is associated with increased risks of impaired physical and cognitive function, falls, cardiovascular events, and mortality. This has led to the development of interventions aimed at reducing ACB through the deprescribing of anticholinergic drugs. However, little is known about the implementation issues that may influence successful embedding and integration of such interventions into routine clinical practice. In this paper, we present the protocol for our systematic review that aims to identify the qualitative evidence for the barriers and facilitators to reduce ACB from the perspectives of patients, carers, and healthcare professionals. A comprehensive search strategy will be conducted across OVID Medline, EMBASE, PsycInfo, and CINAHL. The review will be conducted in accordance with ENTREQ (Enhancing Transparency in Reporting the Synthesis of Qualitative Research) and has been registered with PROSPERO (Registration CRD42018109084). Normalization process theory (NPT) will be used to explore, understand, and explain qualitative data in relation to factors that act as barriers or facilitators to ACB reduction.
AB - Anticholinergic drugs are prescribed for a range of conditions including gastrointestinal disorders, overactive bladder, allergies, and depression. While in some circumstances anticholinergic effects are therapeutic, they also pose many undesired or adverse effects. The overall impact from concomitant use of multiple medications with anticholinergic properties is termed anticholinergic burden (ACB). Greater ACB is associated with increased risks of impaired physical and cognitive function, falls, cardiovascular events, and mortality. This has led to the development of interventions aimed at reducing ACB through the deprescribing of anticholinergic drugs. However, little is known about the implementation issues that may influence successful embedding and integration of such interventions into routine clinical practice. In this paper, we present the protocol for our systematic review that aims to identify the qualitative evidence for the barriers and facilitators to reduce ACB from the perspectives of patients, carers, and healthcare professionals. A comprehensive search strategy will be conducted across OVID Medline, EMBASE, PsycInfo, and CINAHL. The review will be conducted in accordance with ENTREQ (Enhancing Transparency in Reporting the Synthesis of Qualitative Research) and has been registered with PROSPERO (Registration CRD42018109084). Normalization process theory (NPT) will be used to explore, understand, and explain qualitative data in relation to factors that act as barriers or facilitators to ACB reduction.
KW - Anticholinergics
KW - deprescribing
KW - intervention development
KW - qualitative research
KW - systematic review
UR - http://www.scopus.com/inward/record.url?scp=85071079302&partnerID=8YFLogxK
U2 - 10.1111/jebm.12359
DO - 10.1111/jebm.12359
M3 - Article
C2 - 31441236
VL - 12
SP - 227
EP - 231
JO - Journal of Evidence-Based Medicine
JF - Journal of Evidence-Based Medicine
SN - 1756-5383
IS - 3
ER -